FDA Food and Drug Administration - Search News

FDA, Axsome and migraine

Hosted on MSN · 7h

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. The oral drug, branded Symbravo, was approved for the acute treatment of the condition characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.

Business Insider · 10h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Investing.com on MSN · 9h

FDA approves new migraine treatment SYMBRAVO

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®,

Seeking Alpha on MSN · 9h

Axsome gets FDA approval for Symbravo for migraine

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,

FDA, opioid

FDA approves new type of non-opioid pain medication

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is

FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain.

The Washington Post · 7h

FDA approves new, non-opioid painkiller Journavx

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

This chocolate recall has been upgraded to FDA’s highest risk level

STATEN ISLAND, N.Y. — A December 2024 chocolate recall has been upgraded to highest risk level by the U.S. Food and Drug ...

4don MSN

Food and Drug Administration wants to put nutrition labels front and center on food products

The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers ...

The FDA banned Red 3 food coloring. A scientist explains the dye’s history and health risks

Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S.

2d

FDA raises alert on listeria-tainted broccoli sold at Walmart over risk of ‘death’

The recall affects 12-ounce bags of the product, which were sold in 20 states and pose serious health risks if consumed.

Hosted on MSN2d

New Maintenance Dosing Option for Alzheimer's Drug Leqembi Offers Flexibility

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results